Since Deng et al. developed EpCAM-specific CARs showing significant tumor growth inhibition and prolonged survival in mouse xenograft models using the PC3 human prostate cell line, the antigen became a new target of interest in cellular therapy [50]. This evidence concerns the gene EPCAM and neoplasm.